Skip to main content
Panacea Biotec Ltd. logo

Panacea Biotec Ltd. — Investor Relations & Filings

Ticker · PANACEABIO ISIN · INE922B01023 LEI · 3358001FA81ZQYDLO796 BSE.NS Manufacturing
Open in API
Filings indexed 794 across all filing types
Latest filing 2022-11-07 Regulatory Filings
Country IN India
Listing BSE.NS PANACEABIO

About Panacea Biotec Ltd.

https://www.panaceabiotec.com

Panacea Biotec Ltd. is a research-driven health management company specializing in the development, manufacturing, and marketing of vaccines, biopharmaceuticals, and pharmaceutical formulations. The organization focuses on therapeutic segments including organ transplantation, nephrology, oncology, diabetes, and pain management. Its vaccine portfolio supports global immunization initiatives, addressing diseases such as polio and hepatitis B through partnerships with international health agencies. The company operates integrated research and development centers and manufacturing facilities that adhere to international quality standards. Panacea Biotec emphasizes the creation of innovative drug delivery systems and complex generics to improve patient outcomes. Its operations are characterized by a commitment to biotechnology-led medical solutions and the production of affordable, high-quality therapeutic products for diverse global markets.

Recent filings

Filing Released Lang Actions
General updates
Regulatory Filings
2022-11-07 English
Board Meeting — Financial results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming Board Meeting scheduled for November 14, 2022, to approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2022. It references regulatory compliance under SEBI LODR Regulations and mentions the closure of the trading window for insiders. The document does not contain the financial results themselves but announces the meeting where these results will be approved. The document length is short (2197 characters) and serves as an announcement rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification to exchanges about an upcoming event, not the actual financial report or earnings release.
2022-11-04 English
Press Release
Regulatory Filings
2022-10-10 English
General updates
Regulatory Filings Classification · 90% confidence The document contains only placeholders for images and no textual content or substantive information. The length is very short (216 characters) and there is no indication of any report, announcement, or detailed information. Given the absence of content, it cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2022-10-07 English
General updates
Regulatory Filings
2022-10-07 English
Demise
Regulatory Filings Classification · 100% confidence The document text is extremely short (59 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific report type. Given the lack of content, the document cannot be classified as a report or announcement. According to the rules, such minimal or empty content defaults to Regulatory Filings (RNS) as a fallback category.
2022-10-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.